Thermo Fisher Scientific To Buy Solventum's Purification And Filtration Business For $4.1 Bln Cash

SOLVENTUM

81.00 EUR 1.89%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Thermo Fisher Scientific Inc. (TMO) announced Tuesday that the company has entered into a definitive agreement with Solventum Corp. (SOLV) to acquire its Purification & Filtration business for approximately $4.1 billion in cash.

Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

The Solventum business operates globally with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, and has approximately 2,500 colleagues. In 2024, Solventum's Purification & Filtration business generated approximately $1 billion of revenue.

Solventum's Purification & Filtration business is highly complementary to Thermo Fisher's bioproduction business. The innovative filtration portfolio broadens Thermo Fisher's capabilities in the development and manufacturing of biologics, spanning upstream and downstream workflows.

The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Once the transaction closes, Solventum's Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.

Solventum's Purification & Filtration, as part of Thermo Fisher, is expected to generate mid- to high-single digit organic growth and the application of the PPI Business System will enable strong margin expansion and meaningful synergy realization.

In the first year of ownership, the transaction is expected to be dilutive to adjusted EPS by $0.06. Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period.

This reflects the very strong day one cost synergies when Solventum's allocated segment costs are replaced by lower run rate costs within Thermo Fisher, partially offset in year one by one-time business stand up costs.

Thermo Fisher expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year five following the close.

The expected long-term business growth, margin expansion opportunity and synergy realization make the financial returns on the transaction very compelling with a double-digit internal rate of return.